Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects

Summary: Hydroxyurea (HU), an FDA-approved drug for treating sickle cell disease, is used as an antitumor drug alone and together with conventional chemotherapeutics or radiation therapy. HU is used primarily to treat myeloproliferative diseases because it inhibits the enzyme ribonucleotide reductas...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Gang Cheng, Micael Hardy, Paytsar Topchyan, Ryan Zander, Peter Volberding, Weiguo Cui, Balaraman Kalyanaraman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2021-06-01
coleção:	iScience
Assuntos:	Drugs Organic chemistry Biological sciences Immunology
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589004221006416
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!